Olema Oncology, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
7.36
-0.20 (-2.65%)
At close: Nov 16, 2026, 4:00 PM EST
7.50
+0.14 (1.90%)
After-hours: Nov 16, 2026, 6:58 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

OPERA-01 is expected to read out in Q1, testing phase II results in ESR1-mutant and wild-type disease; OPERA-02 enrollment is robust, with a possible sample-size increase after December control-arm data. Launch preparations target mid-2028, subject to OPERA-01 results.

Operator

Thanks, everyone. Sean, thank you very much for being here. Here we have Olema Oncology CEO, Sean. You guys have had a lot going on, and I feel like we're finally getting to the point where we can actually talk about your data and not someone else's data. Must feel pretty good.

Sean Bohen
CEO, Olema Oncology

Yeah. We're very confident in the data we've generated to date, and it's a classic question that we have in oncology, which is, are you able to replicate that phase II data in the phase III setting? And obviously in Q1 for OPERA-01, the second line, second, third line study, we will have that readout. OPERA-02, which is the first line study with KISQALI, is enrolling extremely robustly.

Operator

Yeah. Can we maybe talk to that before we get into the OPERA-01 stuff?

Sean Bohen
CEO, Olema Oncology

Yeah.

Operator

PERSEVERA didn't work out. SERENA-4 didn't work out. The fact that, I think in the press release on Monday or earlier this week, I can't remember which day it was, but you guys actually said that enrollment is accelerating. Can you speak to why, especially in the wake of some pharma setbacks?

Sean Bohen
CEO, Olema Oncology

Yeah. Why is that? One thing that you There are a couple reasons for it.

It is absolutely true that persevERA was a negative trial.

Right? It did not meet its hazard ratio. It didn't get its p-value. It is also absolutely true that there's evidence of activity in that trial, right? There are negative trials where you go, "Wow, this really doesn't do anything. And to be perfectly honest, if that had been the result in persevERA, I think we would have some soul searching to do.

Operator

Yeah. I mean, five months kind of was the bar going into it.

Sean Bohen
CEO, Olema Oncology

Five months is absolutely practice changing.

The challenge is that their hazard ratio missed by a few hundredths, actually. There is clear evidence of activity. Now, there is a design flaw in that trial, and the design flaw is including endocrine-resistant patients. If you look at their tables, that is the TFI treatment-free interval, less than 12 months. Those really aren't first-line patients. Those are endocrine-resistant patients, and they're treated actually as second-line patients in the practice guidelines. Where those patients come from is they received an adjuvant therapy, they stopped that adjuvant therapy, they then went on to develop metastatic disease, but that metastatic disease occurred within the first year of their completion. Those patients generally, as I said, are second line. We don't have those patients in OPERA-02. We never did from the beginning, actually almost no one, because of the treatment guidelines.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

One thing I think that you have to realize is that, first of all, our phase II data, one year in patients post-CDK4/6 progression, mostly wild type, 30% two prior CDK4/6s. So our phase II data is compelling. The tolerability from that looks like KISQALI plus AI, so there is not a signal there that has people concerned about giving that combination. Then very simply, the control arm is the global standard of care. Right? If you go onto this trial, you get randomized between KISQALI plus letrozole, which is the global standard of care, versus KISQALI plus palbociclib, and the investigators are very interested in the data we've seen in the signal, though not positive that persevERA showed.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

I think that's why you get that level of enthusiasm.

Operator

Is this fast enrollment than maybe I expected, but maybe not what you expected? Could this maybe lead to the study getting to a point to read out a little bit earlier?

Sean Bohen
CEO, Olema Oncology

It could, with some caveats. Caveat one is, we may change the study.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

The way we would change the study would be to increase the number of patients enrolled.

Okay, why would we do that, and what are we waiting for? We would do that because the assumptions we use for the performance of the control arm are fairly old. They are really the registrational trials for KISQALI and the other CDK4/6 inhibitors. The median PFS in that was a little over two years, 24, 26 months. It is very common in oncology, as you well know, that a drug or regimen performs better over time. Oncologists are very, very good at learning how to manage toxicity, maintain dose intensity, decrease discontinuations, and when you give the medicine better, it works better.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We are looking for more contemporaneous data sets. One is persevERA, which was about 29 months, so we saw a little bit of a signal there.

SERENA-4, the patients are very similar to OPERA-02.

We think that control arm, again, IBRANCE plus AI, is a good indicator. We are going to wait for that data, which is at San Antonio. It is at the beginning of December, and then we will reevaluate. Obviously, if we enroll some more patients, that takes-

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

a little longer. Not a lot longer, because we're enrolling fast.

But then the readout is really dependent on event rate.

Operator

Yeah. Makes sense.

Sean Bohen
CEO, Olema Oncology

Yep.

Operator

I know OPERA-01 is really what investors are most focused on right now.

Sean Bohen
CEO, Olema Oncology

Yes.

Operator

Yeah. Have to get through that first.

Sean Bohen
CEO, Olema Oncology

Yep.

Operator

Seems like with OPERA-02, you guys are positioning yourself very well to pull it off, if it could be pulled off, based on design of the trial. A lot of the conversations I have been having with investors on OPERA-01 is very similar. You guys have strategically designed this study to probably most properly do this experiment of if an oral SERD can win in the wild-type, ESR1 wild-type setting. Can you maybe take a second to walk us through how you guys.

Sean Bohen
CEO, Olema Oncology

What we did?

Operator

approach that? Yeah.

Sean Bohen
CEO, Olema Oncology

Yeah, what we're doing. So, obviously, the basis for this is the design of the drug. This is a monotherapy trial, so one of our key attributes, obviously, is our combinability. Obviously, in OPERA-02, we think that's a massive thing.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

We present. We've got two more combos now, everolimus and atirmociclib. We'll present at San Antonio, but we've done palbo, ribo, alpelisib, KAT6. We'll get to that.

Operator

We'll get into all those combos.

Sean Bohen
CEO, Olema Oncology

We'll get there. We're doing all of these combinations, and we find that we are able to maintain exposure and not enhance toxicity, which is unique. That doesn't really apply to OPERA-01, right?

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Because it's a monotherapy trial. We think that our higher exposure, and we've now updated this with hundreds of patients and data, our half-life is 14 days. We have a much higher exposure than anybody else. Then we're a complete estrogen receptor antagonist. It is our thesis that we're completely locking down the receptor more effectively than others are. The phase II data, 7.3 months median PFS in mutant, 5.5 in wild-type, looks differentiated. It's the classic question, does the phase II replicate in phase III? That's what we're going to find out.

Operator

Yep.

Sean Bohen
CEO, Olema Oncology

But with regard to the trial design, there was one other thing that others have not done that we thought was really important, which is we truly are treating two different populations here, post-progression on CDK4/6 plus AI. ESR1 mutant, where obviously others have had some modest success, about two-month prolongation of PFS, and ESR1 wild-type, where there has been no success.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Right? There is some confusion there. Some people think, investors think, "Oh, in the ESR1 wild-type, the estrogen receptor isn't doing anything anymore." Very clearly not the case, because when you give a targeted therapy, you always have to give an endocrine therapy with it. The question isn't, is the estrogen receptor not doing anything? It is doing something. Is it doing enough that if you inhibit it, you'll get the benefit?

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

That's what we're trying to answer. The way we answer it is through statistical design. When you go into the trial as a patient investigator, it just looks like one trial. You take the patients who have progressed on CDK4/6, you randomize them, they get fulvestrant or exemestane, it'll be mostly fulvestrant, or palazestrant. You treat them and you follow for PFS. When you get to the analysis, it almost looks like two trials.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Because we analyze the mutant and the wild-type population separately, so that the trial actually, interestingly, has a variety of positive outcomes. You could, what we hope, you could hit mutant and wild-type.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

That's not confusing. You could hit mutant only, not hit wild-type. That's a positive trial. Not biologically, but statistically. Biologically, this makes no sense, what I'm about to say. You could hit wild-type only, not hit mutant, and that would be a positive.

Operator

Wouldn't that be something?

Sean Bohen
CEO, Olema Oncology

I would have no idea what that meant, and that would be a nice result.

Operator

An upgrade?

Sean Bohen
CEO, Olema Oncology

but it doesn't make any biological sense.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

But it is the statistical.

Operator

And these two endpoints, do you think they would not influence whether you got an approval in ESR1? So if you hit in one but not the other, the other endpoint is still safe from a regulatory perspective?

Sean Bohen
CEO, Olema Oncology

Well, that is what has happened with the others, right? Always in mutant.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

In that case, of course, and biologically, that makes more sense. But no, that is it. The thing that we are doing, though, is what is really different is we are really giving that chance to test in the wild-type.

Operator

Yeah. As far as enrollment.

Sean Bohen
CEO, Olema Oncology

Yeah

Operator

No prior chemo.

Sean Bohen
CEO, Olema Oncology

Right

Operator

at least six months

Sean Bohen
CEO, Olema Oncology

In the advanced setting, yeah

Operator

at least six months of response to their prior line of endocrine therapy, correct?

Sean Bohen
CEO, Olema Oncology

Yeah.

Operator

How do you think that would maybe set you up for the best possibility chance of success here?

Sean Bohen
CEO, Olema Oncology

Right. What has been used by some others, it was not used in EMERALD, the Radius Menarini trial, but some others have used those criteria. You are trying to select against those truly endocrine-resistant patients. We know from a variety of datasets, but probably most best the EMERALD retrospective, patients who an oncologist decided they need chemotherapy at some point for their metastatic disease, they really just do not do well.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

No matter what treatment they get. That is one selection. The six months is a little bit of a compromise between you are rolling quickly enough and trying to select out patients who are just, again, truly endocrine-resistant.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

And are unlikely to benefit from endocrine monotherapy. We don't think they're great selection, but we hope it does give us some.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

What you're really trying to do is you're trying to It's partly the outcome of the trial, but it's partly trying not to enroll patients who you really don't think are going to benefit from these therapies.

Operator

Yeah. So, as far as outcomes, investors seem to feel pretty confident you're going to hit an ESR1 mutant.

Sean Bohen
CEO, Olema Oncology

Yeah.

Operator

Then it really just comes down to, is the safety meaningfully better than elacestrant, competition in the commercial setting? But investors seem to think that the ESR1 wild-type is a bit of a coin flip. Do you agree with that sentiment, or do you think it's designed to maybe be a little bit more than a coin flip probability of success-wise?

Sean Bohen
CEO, Olema Oncology

So first of all, with regard to the mutant- This is oncology. Efficacy drives. Others have definitely seen a benefit, and this is progress for patients, but it's two months. It's two months prolongation.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Sometimes, imlunestrant's 1.7.

There is an opportunity to differentiate there based on efficacy.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

If you can, 7.3, will we duplicate that? That looks really good.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

You don't quite have to get that far, but you could differentiate on efficacy. I think there's an opportunity to differentiate in the mutant. Going to the wild type, I think first of all, investors are absolutely right. The probability of success has to be higher in the mutant than the wild type.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

If you just look at our phase II data, it was 7.3 versus 5.5. That is two months difference.

Right? If you just look at that, you would say that your probability is higher.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

You then go back to precedent. Remember, many of the drugs that have succeeded in the mutant are not complete antagonists, so there is a mechanistic difference, and even imlunestrant, which is one, is limited in its exposure. So there are molecular and pharmacological differences there. But the fact that they were able to succeed in mutant even with that, I think.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

Makes mutants higher PTS.

Operator

Makes sense.

Sean Bohen
CEO, Olema Oncology

We have. Look, we are doing the experiment the way we are because we have some confidence based on our phase II data that there is an opportunity in the wild type.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We will have to see.

Operator

Does this mean an oral option could be available to any patient ER-positive breast, post-frontline therapy?

Sean Bohen
CEO, Olema Oncology

It does.

Operator

Would you immediately start thinking about your KAT6 inhibitor? Maybe we shouldn't be doing this fulvestrant combo. Maybe we go all in on palazestrant.

Sean Bohen
CEO, Olema Oncology

We're thinking about that now. We're thinking about that now. Let me back up.

Operator

But just as a combination backbone, like the implications of hitting in both endpoints.

Sean Bohen
CEO, Olema Oncology

Yes. So the first implication in hitting in both endpoints is that you now have an oral endocrine option for both patients.

There's obviously a market revenue implication, which is you go from a $2 billion, approximately, annual market, which is ESR1 mutant, with competition in it. Opportunity to differentiate, but there's competition there, to a $5 billion market, $3 billion of which doesn't have any competition. Right? That's a massive difference. The $2 billion for where we are, our company size and stuff, is still.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

A great opportunity. But you go to five and no competition in part of it, that's a big deal. With regard to KAT6 and palazestrant, we're testing it now.

The preclinical data suggests that the thing you want to combine with for inhibition of KAT6 is palazestrant.

Not fulvestrant.

Operator

I mean, oral is a clear deal.

Sean Bohen
CEO, Olema Oncology

Oral's better.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Oral's better, and that's driven by efficacy. It's oncology. That is a real differentiator.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

As well. The testing is ongoing. At San Antonio, you will not see any of the data.

The reason is that palazestrant OP-3136 is a novel combo.

It moves a little more slowly.

Operator

Makes sense.

Sean Bohen
CEO, Olema Oncology

Than fulvestrant.

OP-3136, where you will see the early data.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Pala combo, I would like mid-year next year, maybe.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

We will be able to share that. The new NUBEQA, the prostate cancer, that enrollment is starting in the near future. That, the soonest, maybe end of year next year. That is on a different timeline.

Operator

How fast are you guys ready to file on the back of OPERA-01? Are you already working towards commercial readiness? Assuming that at least one of these endpoints is going to hit.

Sean Bohen
CEO, Olema Oncology

Right. Yeah. Yes, we are working on both.

I should say, in terms of filing, we are working on being able to file U.S. and ex-U.S.

In terms of commercialization, we are U.S.-focused.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

We will seek a collaborator.

To we want to be able to file because we don't want to lose time, but we'll seek a collaborator to launch and promote.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

ex-U.S. So we have a commercial, a small but mighty commercial team preparing for launch. We assume that we're going to be able to launch in 2028, maybe mid-year.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

It does depend upon the readout

as you said, of course, of OPERA-01. Those launch preparations are underway. Obviously, the OPERA-01 readout, what is the readout

exactly accelerates and potentially changes the scope of those efforts.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

But again, that's not that far off.

Operator

Yeah. No, time's flying. I can't believe we're almost at San Antonio Breast, which brings me to my transition and

Sean Bohen
CEO, Olema Oncology

Oh, yeah.

Operator

the nearest term catalyst that you guys have. Can you run us through the three posters that you are going to have there and maybe set expectations for how much data to expect?

safety, PK? Will there be efficacy across these?

Sean Bohen
CEO, Olema Oncology

Yeah. Let us do the palazestrant combos first. Again, as I mentioned, one of the attributes of palazestrant that we really designed in from the beginning, but have very actively tested, is combinability. Just reminding everyone that until you decide to give chemotherapy, you always give an endocrine agent.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

All of the targeted agents, PI3 kinases, AKT, mTOR, KAT6,

when it gets there, these things are always combined with an

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

endocrine agent. We've always viewed that combinability as a key property, because we figure you want to give the best targeted agent for the line of therapy or maybe the patient's genetics. Tumor genetics. But you always want to give it with the best endocrine therapy. We also note that others have had trouble. They just don't combine well. Sometimes that's PK interactions, old school pharmacology. Sometimes it's toxicity enhancement.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We haven't seen those things. Now, two of the posters are expanding on that. We have an everolimus data set. The everolimus data set is pretty mature.

Operator

Mm-hmm. Okay.

Sean Bohen
CEO, Olema Oncology

You are going to get Kaplan-Meier, PFS.

Obviously the tolerability.

I think people will, I think, find that interesting.

Operator

I think so. Yeah.

Sean Bohen
CEO, Olema Oncology

We break up by mutant and wild type. That will be interesting for people.

Operator

Mm-hmm. Okay.

Sean Bohen
CEO, Olema Oncology

That, again, is a post-CDK4/6 setting.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

The atirmociclib, reminding everyone, atirmociclib is the CDK4 selective molecule being developed by Pfizer. What they are testing in phase III is, by being more selective for inhibiting CDK4 over CDK6, it is very clear that they dial down neutropenia.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

The question is, do you enhance efficacy by hitting CDK4 harder? That is being tested. For us, we are looking at that is this the life cycle of palazestrant? You will see the initial combination data with the atirmociclib. Enrollment is completed on that. Tolerability, you will see sort of initial efficacy, kind of response rate stuff.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

That's a mixture of post-CDK4/6 and frontline patients. These patients, some of them are going to be on for a long time.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

So that level of maturity won't be there. Everolimus is more mature.

Operator

So think of it more as a first look at ORR, but not necessarily durability yet?

Sean Bohen
CEO, Olema Oncology

No, I don't think you'll see durability. I think, again, you're in a mixed patient population. It's really, the main purpose is to show that once again, here we are combinable.

Operator

Mm-hmm. Okay.

Sean Bohen
CEO, Olema Oncology

Then we share what we have

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

for efficacy.

Operator

Makes sense.

Sean Bohen
CEO, Olema Oncology

That is the way we do it. The KAT6 combination will update our monotherapy. That, again, is primarily breast. We will show our first fulvestrant combo data set. This, again, is from phase I-B. It is at multiple dose levels.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

Of KAT6. Fulvestrant is always given full dose. So again, you will get combinability from the tolerability standpoint. An expansion of the tolerability data set.

Operator

Will this just be the breast patients? I know at ASCO you showed a mix.

Sean Bohen
CEO, Olema Oncology

The fulvestrant combo is only breast.

Right.

Operator

Obviously, yeah.

Sean Bohen
CEO, Olema Oncology

Yes.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Right. The prostate, that NUBEQA is starting.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

That may be end of year next year.

Operator

Okay. But as far as the mono safety?

Sean Bohen
CEO, Olema Oncology

The mono safety, we just use everybody.

Operator

Basket. Okay.

Sean Bohen
CEO, Olema Oncology

We've got.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Yeah, which is interesting because we kind of got a hint that the tolerability might be a little different in breast versus prostate.

Operator

Yeah, I remember you guys saying that at ASCO.

Sean Bohen
CEO, Olema Oncology

Yeah.

Operator

That is why I was asking.

Sean Bohen
CEO, Olema Oncology

Because the prostate patients are older. Some of them have had therapies like prior PLUVICTO.

Which is not a bone marrow friendly.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

Therapy, even though we saw activity there. You will get some initial kind of response rate data. Remember, multiple dose levels. I think what are investors going to do? They are going to compare with Pfizer. Remember, this is not a phase II. This is multiple dose levels. The other thing I would say is these are more heavily pre-treated patients. I think that. But we are pretty comfortable with it.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

Palazestrant is enrolling. Mid-year next year, we think we will have data. But that is a really interesting thing because maybe the phase III here is not fulvestrant. Maybe it is palazestrant.

Operator

Yeah. I think hitting across all in OPERA-01

Sean Bohen
CEO, Olema Oncology

Yeah

Operator

It would be silly not to take that path.

Sean Bohen
CEO, Olema Oncology

Well, yeah, that's a no-brainer. That makes it really easy. We'll see.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We'll see how that goes. But even if you don't, it does change the regulatory pathway. But even if you don't get that in OPERA-01, depending upon the data you see with the combo with KAT6

Operator

You could still pursue well.

Sean Bohen
CEO, Olema Oncology

Yes, absolutely.

Operator

Okay. I've been getting questions from investors since the San Antonio Breast titles went out.

On what the bar is for the fulvestrant plus KAT6 inhibitor. We've seen Pfizer's combination show roughly around, I think it was around 37%. You're also saying now that was in, you're treating more heavily pre-treated patients.

Sean Bohen
CEO, Olema Oncology

Yeah.

Operator

How should we think about that. Or maybe what would your bar be for internal conviction.

Sean Bohen
CEO, Olema Oncology

Well, first of all, you have to think about their earlier data. It is interesting with KAT6. The responses do not always come so early. Which is kind of interesting. Remember that their ASCO presentation was 30%. Their publication then was 37.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

All that had changed was time.

Operator

Yeah. It's not the only epigenetic mechanism where we see that.

Sean Bohen
CEO, Olema Oncology

They all do that.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

They all do that, which is kind of funky.

But you do have to-

Operator

But also kind of good, because if it takes time to get to that-

Sean Bohen
CEO, Olema Oncology

No, no. If you're able to stay on for that long-

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

it's fine.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We really look at more as the 30%.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

Recognizing, again, that pretty much that patient population was one prior line of therapy.

They were post-CDK4/6

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

plus AI and progressions. But in a phase I-B data set, you get patients who've been.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

through more therapeutic options. We know for a fact that responsiveness goes down.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

with more prior therapies. I think that's one thing to look at. The other thing is, obviously, we're multiple dose levels. We haven't selected a dose yet for OP-3136. We started at two. We are at 80. It may very well be, we will see, but it may very well

Operator

Where did you start the fulvestrant combination?

Sean Bohen
CEO, Olema Oncology

You will see.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

You'll see where we started and what we have so far. The palazestrant's a little more complicated because you had to dose escalate both because it's a novel combination.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

It's enrolling. It's doing great.

Operator

Okay.

Sean Bohen
CEO, Olema Oncology

It's a little bit behind the fulvestrant combination. I do think there will be an opportunity as we get there, when we select a dose or a couple of doses to compare, then obviously the expansion.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

Portion will commence. Our objective here, the reason that we got into combos so quickly is, we see multiple flaws with Project Optimus. But one of the major flaws is it is designed to choose dose based on monotherapy. Why would you do that for a drug you never ever intend to give as a monotherapy?

Operator

That's fair.

Sean Bohen
CEO, Olema Oncology

You really want to be testing a regimen you would test-

in a clinical setting. What we're trying to do is accelerate into that.

Operator

Okay. I'm assuming that we should see enough safety to maybe increase conviction that maybe you can combine with a CDK4/6?

Sean Bohen
CEO, Olema Oncology

Yeah. I mean, I think-

Operator

But it's complicated?

Sean Bohen
CEO, Olema Oncology

You'll see what safety we have.

I think that the safety for really making that determination, and it's in the trial, as you know, that arm is in there. That data really has to come from when you've selected a dose.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

of OP-3136.

Right? It's a question of when you've selected a dose, what is the tolerability at that dose? And in particular, because the dysgeusia, while a real thing, a class effect, epigenetically, more broadly actually, that isn't the thing that's going to determine if you can.

Operator

Okay

Sean Bohen
CEO, Olema Oncology

combine with CDK4/6. What will determine is the bone marrow effect.

Operator

Okay. As far as the fulvestrant combo, how close are you to kind of settling on a dose?

Sean Bohen
CEO, Olema Oncology

We got a ways to go. I mean, we just

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

got a ways to go. I mean, our exposure is very high. We very clearly have

our well in active range. You will see that in the poster. We just need to collect more data.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

You only get to do this once.

Operator

Mm-hmm. You want to do it right.

Sean Bohen
CEO, Olema Oncology

It is very important to do it well.

Operator

Yep. The KAT6 space, some investors highlight, has gotten pretty crowded. We are also seeing some KAT6/7s. Pfizer is obviously in the lead with their KAT6 in the clinic first, in phase III.

Sean Bohen
CEO, Olema Oncology

For sure.

Operator

Where do you guys believe you stand from a competitive positioning perspective?

Sean Bohen
CEO, Olema Oncology

Right. The KAT6/7 thing is an interesting thing. We are a KAT6/7. So is Pfizer, by the way. Pfizer is probably a KAT5, 6A, 6B, seven, eight. We're kind of more of a 6A, 6B, seven.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We hear a lot, everybody's got one now.

We actually have data.

Operator

Yeah

Sean Bohen
CEO, Olema Oncology

First of all. Beyond that, we have this opportunity to combine with palazestrant.

We'll see how that plays out, obviously, but the preclinical data suggests that's a real advantage. We are the only ones that can do it. The other thing that was really interesting, we really debated putting the prostate cancer patients on the trial or not. The preclinical data was compelling. Our Chief Scientific Officer was like, "We got to do this. One chance, we do it.

We have monotherapy activity. That led to the NUBEQA collaboration with Bayer. I think we have multiple ways to differentiate. Our tolerability did look better. That needs to be expanded. You need to do it at the dose.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Remember, Pfizer at their five milligram dose has 55% discontinuations or dose reductions, mostly due to cytopenias. I think there's a real opportunity there. We have lots of ways to potentially differentiate here.

Operator

Seems like internal conviction for KAT6 is pretty high.

Sean Bohen
CEO, Olema Oncology

It is really high. External conviction is really high. Our enrollment is crazy.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

We have waiting lists because we are doing this dose escalation still. So when you open it up, it is just going to dose.

Operator

Any type of timeline you can provide for when you might be ready to move the KAT6 into a registrational trial?

Sean Bohen
CEO, Olema Oncology

We got to get a dose.

Operator

Or are we too early?

Sean Bohen
CEO, Olema Oncology

We got to get a dose. As soon as we get a dose-

Operator

I'll keep asking you that every quarter.

Sean Bohen
CEO, Olema Oncology

I think we can get pretty quick. You can ask. That's a fair question.

Operator

As far as what cash runway supports right now?

Sean Bohen
CEO, Olema Oncology

Yeah. We just, earlier this week, did our Q3, had $414 million cash at the end. That gets us sort of into the launch window for palazestrant, but OPERA-01 has to be positive, of course, fileable in order to do that. Of course, you don't want to go into launch running on fumes.

Operator

Yeah.

Sean Bohen
CEO, Olema Oncology

Access to capital is important. But again, the equity isn't the only way to do that, particularly depending on the OPERA-01 outcome.

Operator

Yep.

Sean Bohen
CEO, Olema Oncology

Right. And the need, as I said, to seek a collaborator to get to rest of world. So, yeah, we're in a favorable cash position for what we need. Data from OPERA-01, but also I think lots of data from KAT6 as well.

Operator

Sounds great. Well, a lot coming up around the corner.

Sean Bohen
CEO, Olema Oncology

Lots going on.

Operator

I'm sure there'll be a lot more to chat about in just a couple weeks.

Sean Bohen
CEO, Olema Oncology

There definitely will be.

Operator

Thanks for being here. Thanks everyone for listening. Hope you have a great rest of your conference.

Sean Bohen
CEO, Olema Oncology

Yeah. Thank you, Laura. Appreciate it.

Operator

Of course.